SELLAS Life Sciences Group, Inc. (SLS)

Market Cap	45.01M
Revenue (ttm)	1,000,000
Net Income (ttm)	-38.84M
Shares Out	20.55M
EPS (ttm)	-2.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,044
Open	2.14
Previous Close	2.10
Day's Range	2.13 - 2.23
52-Week Range	2.02 - 9.92
Beta	1.76
Analysts	Buy
Price Target	10.20 (+365.8%)
Earnings Date	Nov 10, 2022

About SLS

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal grow...

• Industry: Biotechnology
• Founded: 2012
• Employees: 11
• Stock Exchange: NASDAQ
• Ticker Symbol: SLS

Full Company Profile

Financial Performance

In 2021, SLS's revenue was $7.60 million, an increase of 300.00% compared to the previous year's $1.90 million. Losses were -$20.70 million, 23.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for SLS stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 365.75% from the latest price.

Price Target

$10.2

(365.75% upside)

Analyst Consensus: Buy

Stock Forecasts